KURA Stock Analysis: Kura Oncology | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 957m USD | 12M Return: 111.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 16.8M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Kura Oncology is a clinical-stage biopharmaceutical company headquartered in San Diego, California, that focuses on developing precision medicines for cancer. Its lead commercial product, KOMZIFTI (ziftomenib), is an oral, selective menin inhibitor, and the company is advancing a broader pipeline that includes Darlifarnib, a Phase 1 farnesyl transferase inhibitor being studied in solid tumors, and KO-7246, a next-generation menin inhibitor being explored in diabetes and cardiometabolic disorders alongside additional menin inhibitor combinations for solid tumors.
As a clinical-stage oncology company, Kura operates within the biotechnology sub-industry, where firms typically rely on capital markets, partnerships, and licensing arrangements to fund long drug development cycles before products generate meaningful revenue. Its lead asset targets the menin protein pathway, which has emerged as a clinically validated target in certain genetically defined leukemias, and the company is seeking to extend this mechanism into solid tumor and non-oncology indications.
- KOMZIFTI commercial launch drives first product revenue ramp
- Darlifarnib and KO-7246 pipeline data readouts near term
- Menin inhibitor competitive landscape intensifies with new approvals
| Net Income: -294.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.40 > 0.02 and ΔFCF/TA -20.02 > 1.0 |
| NWC/Revenue: 729.1% < 20% (prev 933.1%; Δ -204.1% < -1%) |
| CFO/TA -0.12 > 3% & CFO -78.0m > Net Income -294.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.15 > 1.5 & < 3 |
| Outstanding Shares: last quarter (88.6m) vs 12m ago 1.37% < -2% |
| Gross Margin: 93.70% > 18% (prev 99.10%; Δ -5.40% > 0.5%) |
| Asset Turnover: 10.26% > 50% (prev 9.14%; Δ 1.12% > 0%) |
| Interest Coverage Ratio: -200.1 > 6 (EBIT TTM -293.4m / Interest Expense TTM 1.47m) |
| A: 0.80 (Total Current Assets 623.8m - Total Current Liabilities 101.5m) / Total Assets 652.6m |
| B: -1.91 (Retained Earnings -1.25b / Total Assets 652.6m) |
| C: -0.42 (EBIT TTM -293.4m / Avg Total Assets 698.2m) |
| D: 0.20 (Book Value of Equity 107.9m / Total Liabilities 544.7m) |
| Altman-Z'' = -3.60 = D |
| DSRI: 0.27 (Receivables 13.6m/48.7m, Revenue 71.6m/68.0m) |
| GMI: 1.06 (GM 99.10% / 93.70%) |
| AQI: 1.76 (AQ_t 0.02 / AQ_t-1 0.01) |
| SGI: 1.05 (Revenue 71.6m / 68.0m) |
| TATA: -0.33 (NI -294.6m - CFO -78.0m) / TA 652.6m) |
| Beneish M = -3.13 (Cap -4..+1) = AA |
As of July 08, 2026, the stock is trading at USD 11.99 with a total of 3,812,066 shares traded. Over the past week, the price has changed by +9.30%, over one month by +40.07%, over three months by +35.94% and over the past year by +111.09%.
Current recommended Stop Loss: 11.30 (which is 5.8% or 1.3 ATR below the current price).
Kura Oncology has received a consensus analysts rating of 4.53. Therefore, it is recommended to buy KURA.
- StrongBuy: 10
- Buy: 3
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 31.2 | 160% |
P/S = 13.3585
P/B = 8.8624
Revenue TTM = 71.6m USD
EBIT TTM = -293.4m USD
EBITDA TTM = -292.3m USD
Long Term Debt = 9.75m USD (from longTermDebt, last quarter)
Short Term Debt = 1.28m USD (from shortTermDebt, last quarter)
Debt = 38.8m USD (from shortLongTermDebtTotal, last quarter) + Leases 14.5m
Net Debt = -93.4m USD (calculated: Debt 38.8m - CCE 132.2m)
Enterprise Value = 863.6m USD (957.0m + Debt 38.8m - CCE 132.2m)
Interest Coverage Ratio = -200.1 (Ebit TTM -293.4m / Interest Expense TTM 1.47m)
EV/FCF = -3.31x (Enterprise Value 863.6m / FCF TTM -260.9m)
FCF Yield = -30.21% (FCF TTM -260.9m / Enterprise Value 863.6m)
FCF Margin = -364.2% (FCF TTM -260.9m / Revenue TTM 71.6m)
Net Margin = -411.2% (Net Income TTM -294.6m / Revenue TTM 71.6m)
Gross Margin = 93.70% ((Revenue TTM 71.6m - Cost of Revenue TTM 4.51m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.32 (Enterprise Value 863.6m / Total Assets 652.6m)
Interest Expense / Debt = 3.78% (Interest Expense 1.47m / Debt 38.8m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -231.8m (EBIT -293.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.75 (Total Current Assets 623.8m / Total Current Liabilities 108.5m)
Debt / Equity = 0.36 (Debt 38.8m / totalStockholderEquity, last quarter 107.9m)
Debt / EBITDA = 0.32 (negative EBITDA) (Net Debt -93.4m / EBITDA -292.3m)
Debt / FCF = 0.36 (negative FCF - burning cash) (Net Debt -93.4m / FCF TTM -260.9m)
Total Stockholder Equity = 207.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -42.19% (Net Income -294.6m / Total Assets 652.6m)
RoE = -142.0% (Net Income TTM -294.6m / Total Stockholder Equity 207.5m)
RoCE = -135.1% (out of range, set to none) (EBIT -293.4m / Capital Employed (Equity 207.5m + L.T.Debt 9.75m))
RoIC = -42.24% (negative operating profit) (NOPAT -231.8m / Invested Capital 548.8m)
WACC = 9.44% (E(957.0m)/V(995.8m) * Re(9.70%) + D(38.8m)/V(995.8m) * Rd(3.78%) * (1-Tc(0.21)))
Discount Rate = 9.70% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 6.23%
[DCF] Fair Price = unknown (Cash Flow -260.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.21 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -0.43 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.89 | Chg30d=+2.28% | Revisions=+55% | Analysts=9
EPS next Quarter (2026-09-30): EPS=-0.90 | Chg30d=+2.72% | Revisions=+55% | Analysts=9
EPS current Year (2026-12-31): EPS=-3.46 | Chg30d=+1.80% | Revisions=+18% | GrowthEPS=-8.7% | GrowthRev=+40.8%
EPS next Year (2027-12-31): EPS=-2.60 | Chg30d=-1.75% | Revisions=+18% | GrowthEPS=+24.9% | GrowthRev=+125.8%
[Analyst] Revisions Ratio: +46% (up=24, down=8)